Diagnosis and therapy of acute myeloid leukemia in the era of molecular risk stratification

Krishna V Komanduri, Ross L. Levine

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The diagnosis and risk stratification of acute myeloid leukemia (AML) primarily rely on morphologic analysis and assessment of karyotype by chromosome banding analysis. For decades, standard AML induction therapy has utilized the combination of anthracyclines and cytarabine. Despite the use of postremission therapy, less than half of patients with AML will be cured of their disease. Allogeneic hematopoietic stem cell transplantation combines cytoreductive chemotherapy with adoptive immunotherapy and may cure patients who fail chemotherapy alone. Recent advances in next-generation sequencing have yielded important insights into the molecular landscape of AML with normal karyotype. Integrated prognostic models incorporating somatic mutation analyses may outperform prediction based on conventional clinical and cytogenetic factors alone. We review the evolution of risk profiling of AML from the cytogenetic to molecular era and describe the implications for AML diagnosis and postremission therapy.

Original languageEnglish (US)
Pages (from-to)59-72
Number of pages14
JournalAnnual Review of Medicine
Volume67
DOIs
StatePublished - Jan 14 2016

Fingerprint

Chemotherapy
Acute Myeloid Leukemia
Anthracyclines
Cytarabine
Chromosomes
Stem cells
Karyotype
Cytogenetics
Therapeutics
Chromosome Banding
Adoptive Immunotherapy
Drug Therapy
Hematopoietic Stem Cell Transplantation
Mutation

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • Graft-versus-leukemia
  • Induction chemotherapy
  • Next-generation sequencing
  • Postremission therapy
  • Somatic mutation profiling

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Diagnosis and therapy of acute myeloid leukemia in the era of molecular risk stratification. / Komanduri, Krishna V; Levine, Ross L.

In: Annual Review of Medicine, Vol. 67, 14.01.2016, p. 59-72.

Research output: Contribution to journalArticle

@article{31230a937e7d4286b839e209afdb74a7,
title = "Diagnosis and therapy of acute myeloid leukemia in the era of molecular risk stratification",
abstract = "The diagnosis and risk stratification of acute myeloid leukemia (AML) primarily rely on morphologic analysis and assessment of karyotype by chromosome banding analysis. For decades, standard AML induction therapy has utilized the combination of anthracyclines and cytarabine. Despite the use of postremission therapy, less than half of patients with AML will be cured of their disease. Allogeneic hematopoietic stem cell transplantation combines cytoreductive chemotherapy with adoptive immunotherapy and may cure patients who fail chemotherapy alone. Recent advances in next-generation sequencing have yielded important insights into the molecular landscape of AML with normal karyotype. Integrated prognostic models incorporating somatic mutation analyses may outperform prediction based on conventional clinical and cytogenetic factors alone. We review the evolution of risk profiling of AML from the cytogenetic to molecular era and describe the implications for AML diagnosis and postremission therapy.",
keywords = "Allogeneic hematopoietic stem cell transplantation, Graft-versus-leukemia, Induction chemotherapy, Next-generation sequencing, Postremission therapy, Somatic mutation profiling",
author = "Komanduri, {Krishna V} and Levine, {Ross L.}",
year = "2016",
month = "1",
day = "14",
doi = "10.1146/annurev-med-051914-021329",
language = "English (US)",
volume = "67",
pages = "59--72",
journal = "Annual Review of Medicine",
issn = "0066-4219",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Diagnosis and therapy of acute myeloid leukemia in the era of molecular risk stratification

AU - Komanduri, Krishna V

AU - Levine, Ross L.

PY - 2016/1/14

Y1 - 2016/1/14

N2 - The diagnosis and risk stratification of acute myeloid leukemia (AML) primarily rely on morphologic analysis and assessment of karyotype by chromosome banding analysis. For decades, standard AML induction therapy has utilized the combination of anthracyclines and cytarabine. Despite the use of postremission therapy, less than half of patients with AML will be cured of their disease. Allogeneic hematopoietic stem cell transplantation combines cytoreductive chemotherapy with adoptive immunotherapy and may cure patients who fail chemotherapy alone. Recent advances in next-generation sequencing have yielded important insights into the molecular landscape of AML with normal karyotype. Integrated prognostic models incorporating somatic mutation analyses may outperform prediction based on conventional clinical and cytogenetic factors alone. We review the evolution of risk profiling of AML from the cytogenetic to molecular era and describe the implications for AML diagnosis and postremission therapy.

AB - The diagnosis and risk stratification of acute myeloid leukemia (AML) primarily rely on morphologic analysis and assessment of karyotype by chromosome banding analysis. For decades, standard AML induction therapy has utilized the combination of anthracyclines and cytarabine. Despite the use of postremission therapy, less than half of patients with AML will be cured of their disease. Allogeneic hematopoietic stem cell transplantation combines cytoreductive chemotherapy with adoptive immunotherapy and may cure patients who fail chemotherapy alone. Recent advances in next-generation sequencing have yielded important insights into the molecular landscape of AML with normal karyotype. Integrated prognostic models incorporating somatic mutation analyses may outperform prediction based on conventional clinical and cytogenetic factors alone. We review the evolution of risk profiling of AML from the cytogenetic to molecular era and describe the implications for AML diagnosis and postremission therapy.

KW - Allogeneic hematopoietic stem cell transplantation

KW - Graft-versus-leukemia

KW - Induction chemotherapy

KW - Next-generation sequencing

KW - Postremission therapy

KW - Somatic mutation profiling

UR - http://www.scopus.com/inward/record.url?scp=84954501347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954501347&partnerID=8YFLogxK

U2 - 10.1146/annurev-med-051914-021329

DO - 10.1146/annurev-med-051914-021329

M3 - Article

C2 - 26473413

AN - SCOPUS:84954501347

VL - 67

SP - 59

EP - 72

JO - Annual Review of Medicine

JF - Annual Review of Medicine

SN - 0066-4219

ER -